

Clinical Magnetic Resonance First Pass Myocardial Perfusion Imaging - Choosing the optimal sequence

Published: 11-09-2007

Last updated: 08-05-2024

The aim of this study is to directly compare two last generation FPMPI pulse sequences (EPI and SSFP) in a group of patients with suspected CAD.

Ethical review	Approved WMO
Status	Pending
Health condition type	Coronary artery disorders
Study type	Observational invasive

Summary

ID

NL-OMON31268

Source

ToetsingOnline

Brief title

NA

Condition

- Coronary artery disorders

Synonym

coronary artery disease

Research involving

Human

Sponsors and support

Primary sponsor: Vrije Universiteit Medisch Centrum

Source(s) of monetary or material Support: Ministerie van OC&W

Intervention

Keyword: MRI, myocardial ischemia

Outcome measures

Primary outcome

Comparison of image quality and artifacts, intra- and interobserver variability and diagnostic accuracy.

Secondary outcome

NA

Study description

Background summary

Magnetic resonance First pass myocardial perfusion imaging (FPMPI) is an established technique for the evaluation of myocardial perfusion. However, current pulse sequences still have some limitations (triggering or motion artifacts) and ongoing optimization of pulse sequences is required. This project focuses on two last generation sequences, SSFP and EPI, both optimized using parallel imaging.

EPI is faster, and theoretically has less motion artifacts, whereas SSFP has higher signal-to-noise and potentially more reliable semi-quantitative analysis.

Study objective

The aim of this study is to directly compare two last generation FPMPI pulse sequences (EPI and SSFP) in a group of patients with suspected CAD.

Study design

Observational study in which EPI- and SSFP-FPMPI will be done within a period of 2 weeks.

Study burden and risks

The burden is considered low: 1 extra visit for an MR examination of 20

minutes. Risks are negligible. During the study the vasodilating substance adenosine will be infused during 3 minutes, which may lead to mild and short lasting side effects that will be familiar from the first study. MRI is not radiotoxic, and harmful effects of its repeated use or of the contrast agent have not been reported.

Contacts

Public

Vrije Universiteit Medisch Centrum

Postbus 7057
1007 MB Amsterdam
Nederland

Scientific

Vrije Universiteit Medisch Centrum

Postbus 7057
1007 MB Amsterdam
Nederland

Trial sites

Listed location countries

Netherlands

Eligibility criteria

Age

Adults (18-64 years)
Elderly (65 years and older)

Inclusion criteria

All patients aged 30-70, referred for diagnostic FPMPI to the CMR department at the VU Medical Centre are study candidates.

Exclusion criteria

Severe adenosine (heart block > 1st degree), or contrast (allergy) related side effects during initial study).

Study design

Design

Study type: Observational invasive

Masking: Open (masking not used)

Control: Uncontrolled

Primary purpose: Diagnostic

Recruitment

NL

Recruitment status: Pending

Start date (anticipated): 01-06-2007

Enrollment: 60

Type: Anticipated

Ethics review

Approved WMO

Application type: First submission

Review commission: METC Amsterdam UMC

Study registrations

Followed up by the following (possibly more current) registration

No registrations found.

Other (possibly less up-to-date) registrations in this register

No registrations found.

In other registers

Register

CCMO

ID

NL18067.029.07